The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding and Additional Listing

1 Oct 2019 18:06

RNS Number : 4216O
Silence Therapeutics PLC
01 October 2019
 

Director/PDMR Shareholding and Additional Listing

October 1, 2019

 

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on September 28, 2019 1,626 Conditional Share Awards were exercised by Alistair Gray, Non-Executive Director of the Company, at a price of 5p per share. Following this exercise, Alistair Gray is interested in 1,626 ordinary shares, being

 

The Company also announces it has today issued and allotted 1,626 new ordinary shares of 5p each ("New Ordinary Shares") following this exercise of Conditional Share Awards under the 2018 Non-Employee Long Term Incentive Plan. Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on October 7, 2019. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

 

The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 78,325,653. The Company holds no shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Alistair Gray

 

2.

Reason for the notification

a)

Position / status

Non-Executive Director

 

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Silence Therapeutics plc

 

b)

LEI

213800SSURRJBX85SQ91

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares in Silence Therapeutics plc

 

 

 

ISIN for Silence Therapeutics plc Ordinary Shares:

GB00B9GTXM62

 

b)

Nature of the transaction

Exercise of share options over Ordinary Shares in Silence Therapeutics plc

 

c)

Prices(a) and volume(s)

 

Price

Volume

5p

1,626

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

1,626 Ordinary Shares

£81.30

e)

Date of the transaction

28 September 2019

 

f)

Place of the transaction

Outside a trading venue

 

 

  

 

Enquiries:

 

Silence Therapeutics plc

Dr David Horn Solomon, Chief Executive Officer

 

Tel: +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

 

Tel: +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

silencetherapeutics@consilium-comms.com

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke Partners

Peter Vozzo

peter.vozzo@westwicke.com

 

 Tel: +1 (443) 213-0505

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/ 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAXEFEELNFFF
Date   Source Headline
17th May 20115:39 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th May 20115:38 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th May 20115:38 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
16th May 20113:36 pmPRNGrant of options and warrants
16th May 20112:30 pmPRNResult of General Meeting
16th May 20117:00 amPRNResults of Placing and Open Offer
12th May 20115:42 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
27th Apr 20117:06 amPRNPlacing and Open Offer of New Ordinary Shares
27th Apr 20117:01 amPRNFull Year Results for the Year Ended 31 December 2010
26th Apr 20114:40 pmRNSSecond Price Monitoring Extn
26th Apr 20114:35 pmRNSPrice Monitoring Extension
7th Apr 20114:40 pmRNSSecond Price Monitoring Extn
7th Apr 20114:35 pmRNSPrice Monitoring Extension
7th Apr 20111:37 pmRNSTR-1: Notification of Major Interest in Shares
4th Apr 20114:40 pmRNSSecond Price Monitoring Extn
4th Apr 20114:35 pmRNSPrice Monitoring Extension
21st Mar 20118:00 amRNSPF-04523655 Phase 2 Study Results
14th Feb 20114:35 pmRNSPrice Monitoring Extension
7th Feb 20117:00 amRNSOffer Update
21st Dec 20107:00 amRNSYear-end Update
17th Nov 20104:40 pmRNSSecond Price Monitoring Extn
17th Nov 20104:35 pmRNSPrice Monitoring Extension
16th Nov 20104:40 pmRNSSecond Price Monitoring Extn
16th Nov 20104:35 pmRNSPrice Monitoring Extension
15th Nov 20104:40 pmRNSSecond Price Monitoring Extn
15th Nov 20104:35 pmRNSPrice Monitoring Extension
12th Nov 20102:53 pmPRNForm 8.3 - Silence Therapeutics Plc
12th Nov 20101:35 pmBUSForm 8.3 - Silence Therapeutics plc
11th Nov 20101:54 pmPRNForm 8.3 - Silence Therapeutics Plc
11th Nov 201011:49 amRNSHolding in Company
11th Nov 20107:28 amBUSForm 8.3 - Silence Therapeutics plc
5th Nov 20104:40 pmRNSSecond Price Monitoring Extn
5th Nov 20104:35 pmRNSPrice Monitoring Extension
22nd Oct 20107:53 amBUSForm 8.3 - Silence Therapeutics plc
21st Oct 20109:23 amBUSForm 8.3 - Silence Therapeutics plc
20th Oct 20104:40 pmRNSSecond Price Monitoring Extn
20th Oct 20104:40 pmRNSSecond Price Monitoring Extn
20th Oct 20104:35 pmRNSPrice Monitoring Extension
20th Oct 20104:35 pmRNSPrice Monitoring Extension
20th Oct 20103:35 pmBUSForm 8.3 - Silence Therapeutics plc
20th Oct 20107:00 amRNSSilence Therapeutics Receives European RNAi Patent
19th Oct 20101:21 pmBUSForm 8.3 - Silence Therapeutics plc
18th Oct 20104:40 pmRNSSecond Price Monitoring Extn
18th Oct 20104:35 pmRNSPrice Monitoring Extension
15th Oct 20104:27 pmBUSForm 8.3 - Silence Therapeutics plc - Replacement
15th Oct 20104:27 pmBUSForm 8.3 - Silence Therapeutics plc - Replacement
15th Oct 20102:28 pmBUSForm 8.3 - Silence Therapeutics plc
15th Oct 20101:52 pmBUSForm 8.3 - Silence Therapeutics plc
12th Oct 20104:35 pmRNSPrice Monitoring Extension
11th Oct 20105:04 pmBUSForm 8.3 - Silence Therapeutics plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.